Journal article

Working towards a Group A Streptococcal vaccine: Report of a collaborative Trans-Tasman workshop

Nicole J Moreland, Claire S Waddington, Deborah A Williamson, Shiranee Sriskandan, Pierre R Smeesters, Thomas Proft, Andrew C Steer, Mark J Walker, Edward N Baker, Michael G Baker, Diana Lennon, Rod Dunbar, Jonathan Carapetis, John D Fraser

VACCINE | ELSEVIER SCI LTD | Published : 2014


Group A Streptococcus (GAS) infections represent a major public health burden in both developing and developed countries. In Australia and New Zealand GAS associated diseases are serious problems in Indigenous populations and a major cause of health inequality. Political recognition of these inequalities is providing impetus for strategies that reduce GAS disease and the development of a GAS vaccine now has governmental support in both Australia and New Zealand. Accordingly, an expert workshop was convened in March 2013 to consider available data on GAS vaccines. M-protein based vaccines constructed from the hyper-variable N-terminal region (30-valent vaccine) or the conserved C-repeat domai..

View full abstract


Awarded by New Zealand Heart Foundation

Awarded by Biotechnology and Biological Sciences Research Council

Awarded by Medical Research Council

Funding Acknowledgements

We thank all the individuals who freely gave their time to participate in the Trans-Tasman GAS vaccine workshop that formed the basis of this article. The Maurice Wilkins Centre supported the workshop and NM is a New Zealand Heart Foundation (grant no. 1465) research fellow. We also thank Vivian Ward for assistance in preparing the illustration.